AR109539A1 - Sitio de inserción orf70 de ehv - Google Patents
Sitio de inserción orf70 de ehvInfo
- Publication number
- AR109539A1 AR109539A1 ARP170102576A ARP170102576A AR109539A1 AR 109539 A1 AR109539 A1 AR 109539A1 AR P170102576 A ARP170102576 A AR P170102576A AR P170102576 A ARP170102576 A AR P170102576A AR 109539 A1 AR109539 A1 AR 109539A1
- Authority
- AR
- Argentina
- Prior art keywords
- sequence
- homologous
- seq
- interest
- orf70
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16741—Use of virus, viral particle or viral elements as a vector
- C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/12011—Bunyaviridae
- C12N2760/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/12011—Bunyaviridae
- C12N2760/12071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
Abstract
Vacuna (de vector), y en especial, al sitio de inserción ORF70 de EHV (alfaherpesvirus equino 1). También casetes de expresión y vectores relacionados, que son adecuados para expresar genes de interés, en especial, secuencias que codifican un antígeno. Los vectores virales son útiles para producir una composición inmunógena o vacuna. Reivindicación 1: Un casete de expresión caracterizado porque comprende (i) al menos una secuencia de nucleótidos exógena de interés, preferentemente, un gen de interés, con mayor preferencia, una secuencia que codifica un antígeno, por lo cual dicha secuencia de nucleótidos de interés, preferentemente, un gen de interés, con mayor preferencia, una secuencia que codifica un antígeno, está ligada operativamente a una secuencia promotora, y (ii) al menos una región de flanqueo izquierda de ORF70 seleccionada del grupo que consiste en: SEQ ID Nº 13 y una secuencia 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% homóloga y/o idéntica de esta, SEQ ID Nº 15 y una secuencia 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% homóloga y/o idéntica de esta, SEQ ID Nº 17 y una secuencia 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% homóloga y/o idéntica de esta, y (iii) al menos una región de flanqueo derecha de ORF70 seleccionada del grupo que consiste en: SEQ ID Nº 14 y una secuencia 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% homóloga y/o idéntica de esta, SEQ ID Nº 16 y una secuencia 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% homóloga y/o idéntica de esta, SEQ ID Nº 18 y una secuencia 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% homóloga y/o idéntica de aquel.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16189776 | 2016-09-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR109539A1 true AR109539A1 (es) | 2018-12-19 |
Family
ID=57083093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170102576A AR109539A1 (es) | 2016-09-20 | 2017-09-18 | Sitio de inserción orf70 de ehv |
Country Status (18)
Country | Link |
---|---|
US (1) | US10619169B2 (es) |
EP (1) | EP3515481A1 (es) |
JP (2) | JP6952112B2 (es) |
KR (1) | KR102618843B1 (es) |
CN (1) | CN109715204B (es) |
AR (1) | AR109539A1 (es) |
AU (1) | AU2017329669A1 (es) |
BR (1) | BR112019005516A2 (es) |
CA (1) | CA3036291A1 (es) |
CL (1) | CL2019000655A1 (es) |
EA (1) | EA201990711A1 (es) |
MX (1) | MX2019003161A (es) |
NZ (1) | NZ751014A (es) |
PH (1) | PH12019500557A1 (es) |
SA (1) | SA519401350B1 (es) |
TW (1) | TWI817933B (es) |
UY (1) | UY37406A (es) |
WO (1) | WO2018054837A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109715204B (zh) * | 2016-09-20 | 2023-08-22 | 勃林格殷格翰动物保健有限公司 | 新的ehv插入位点orf70 |
TW201823467A (zh) | 2016-09-20 | 2018-07-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | 犬腺病毒載體 |
AR109540A1 (es) | 2016-09-20 | 2018-12-19 | Boehringer Ingelheim Vetmedica Gmbh | Moléculas promotoras para expresar antígenos virales |
EP3515480A1 (en) | 2016-09-20 | 2019-07-31 | Boehringer Ingelheim Vetmedica GmbH | New swine influenza vaccine |
WO2022101679A1 (en) | 2020-11-13 | 2022-05-19 | Boehringer Ingelheim Vetmedica Gmbh | New feline herpes virus vaccine |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US382425A (en) | 1888-05-08 | Brandt | ||
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US3857423A (en) | 1971-12-27 | 1974-12-31 | W Ronca | Topical medicament kit with interlocking components |
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4769331A (en) | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
IE872748L (en) | 1986-10-16 | 1988-04-16 | Arjomari Europ | Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
WO1990001543A1 (fr) | 1988-07-29 | 1990-02-22 | Intracel Corporation | Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo |
CA2003300A1 (en) | 1988-11-21 | 1990-05-21 | Franklin Volvovitz | Skin test and test kit for aids |
WO1990011092A1 (en) | 1989-03-21 | 1990-10-04 | Vical, Inc. | Expression of exogenous polynucleotide sequences in a vertebrate |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
US5552143A (en) | 1989-03-24 | 1996-09-03 | The Wistar Institute Of Anatomy & Biology | Recombinant cytomegalovirus vaccine |
GB9001766D0 (en) | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
US5616326A (en) | 1990-01-25 | 1997-04-01 | The University Court Of The University Of Glasgow | Recombinant canine adenovirus 2 (CAV-2) |
EP0575491B1 (en) | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5997878A (en) | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
US6193983B1 (en) * | 1992-06-01 | 2001-02-27 | The University Of Melbourne | Equine herpesvirus glycoproteins |
US6225111B1 (en) * | 1992-08-07 | 2001-05-01 | Schering Plough Veterinary Corp. | Recombinant equine herpesviruses |
US5741696A (en) | 1992-08-07 | 1998-04-21 | Syntro Corporation | Recombinant equine herpesviruses |
US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
IL108915A0 (en) | 1993-03-18 | 1994-06-24 | Merck & Co Inc | Polynucleotide vaccine against influenza virus |
FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
CA2144040A1 (fr) | 1993-07-13 | 1995-01-26 | Michel Perricaudet | Vecteurs adenoviraux defectifs et utilisation en therapie genique |
FR2711670B1 (fr) | 1993-10-22 | 1996-01-12 | Pasteur Institut | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. |
US5820868A (en) | 1993-12-09 | 1998-10-13 | Veterinary Infectious Disease Organization | Recombinant protein production in bovine adenovirus expression vector system |
WO1995020660A2 (en) | 1994-01-27 | 1995-08-03 | University Of Massachusetts Medical Center | Immunization by inoculation of dna transcription unit |
WO1995030018A2 (en) | 1994-04-29 | 1995-11-09 | Immuno Aktiengesellschaft | Recombinant poxviruses with foreign polynucleotides in essential regions |
FR2725726B1 (fr) | 1994-10-17 | 1997-01-03 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en therapie genique |
FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
FR2730504B1 (fr) | 1995-02-13 | 1997-03-28 | Rhone Poulenc Rorer Sa | Procede de preparation de genomes d'adenovirus recombinants |
FR2731710B1 (fr) | 1995-03-14 | 1997-04-30 | Rhone Poulenc Rorer Sa | Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique |
EP0871755A1 (en) | 1995-03-23 | 1998-10-21 | Cantab Pharmaceuticals Research Limited | Vectors for gene delivery |
FR2732357B1 (fr) | 1995-03-31 | 1997-04-30 | Rhone Poulenc Rorer Sa | Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose |
FR2735789B1 (fr) | 1995-06-23 | 1997-07-25 | Centre Nat Rech Scient | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant |
AU737243B2 (en) | 1996-07-03 | 2001-08-16 | Merial, Inc. | Recombinant canine adenovirus (CAV) containing exogenous DNA |
US6156567A (en) | 1996-07-03 | 2000-12-05 | Merial | Truncated transcriptionally active cytomegalovirus promoters |
US6090393A (en) | 1996-07-03 | 2000-07-18 | Merial | Recombinant canine adenoviruses, method for making and uses thereof |
GB9626029D0 (en) * | 1996-12-14 | 1997-01-29 | Univ Leeds | EVH-1 vectors |
US6183752B1 (en) | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
DE19830141A1 (de) | 1998-07-06 | 2000-01-13 | Regine Heilbronn | Rekombinante Herpesviren für die Erzeugung rekombinanter Adeno-Assoziierter-Viren |
AU758604B2 (en) * | 1998-07-31 | 2003-03-27 | Intervet International B.V. | Attenuated equine herpesvirus |
EP1171617B1 (en) | 1999-04-08 | 2008-02-13 | Novartis Vaccines and Diagnostics, Inc. | Enhancement of the immune response for vaccine and gene therapy applications |
EP1118670A1 (en) | 1999-12-07 | 2001-07-25 | Genethon III | Canine adenovirus vectors for the transfer of genes in targeted cells |
EP1248851A2 (en) | 1999-12-07 | 2002-10-16 | Genethon III | Canine adenovirus vectors for the transfer of genes in targeted cells |
JP2004500810A (ja) | 1999-12-09 | 2004-01-15 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | Il−6様ポリヌクレオチド、ポリペプチド、および抗体 |
DE10116594A1 (de) * | 2001-04-03 | 2002-10-10 | Boehringer Ingelheim Vetmed | Künstliche Chromosomen, die EHV-Sequenzen umfassen |
AU2002342415B2 (en) * | 2001-11-26 | 2007-11-08 | Replikun Biotech Pty Ltd | Flavivirus vaccine delivery system |
AR040601A1 (es) * | 2002-07-19 | 2005-04-13 | Boehringer Ingelheim Vetmed | Mutantes ehv negativos de gm sin elementos heterologos |
FR2845395B1 (fr) | 2002-10-08 | 2008-05-30 | Agronomique Inst Nat Rech | Vecteurs adenoviraux recombinants et leurs applications |
WO2007081336A1 (en) | 2006-01-13 | 2007-07-19 | Five Prime Therapeutics, Inc. | Mammalian vectors for high-level expression of recombinant proteins |
EP2019687B1 (en) * | 2006-03-29 | 2014-03-19 | Merial Limited | Vaccine against streptococci |
JPWO2008032796A1 (ja) | 2006-09-13 | 2010-01-28 | 日本全薬工業株式会社 | 新規イヌ用ワクチン |
WO2009120339A2 (en) | 2008-03-24 | 2009-10-01 | President And Fellows Of Harvard College | Vectors for delivering disease neutralizing agents |
WO2010010107A1 (en) | 2008-07-23 | 2010-01-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel regulatory elements |
US20130197612A1 (en) | 2010-02-26 | 2013-08-01 | Jack W. Lasersohn | Electromagnetic Radiation Therapy |
AR109540A1 (es) | 2016-09-20 | 2018-12-19 | Boehringer Ingelheim Vetmedica Gmbh | Moléculas promotoras para expresar antígenos virales |
CN109715204B (zh) * | 2016-09-20 | 2023-08-22 | 勃林格殷格翰动物保健有限公司 | 新的ehv插入位点orf70 |
TW201823467A (zh) | 2016-09-20 | 2018-07-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | 犬腺病毒載體 |
EP3515480A1 (en) | 2016-09-20 | 2019-07-31 | Boehringer Ingelheim Vetmedica GmbH | New swine influenza vaccine |
-
2017
- 2017-09-18 CN CN201780057791.3A patent/CN109715204B/zh active Active
- 2017-09-18 MX MX2019003161A patent/MX2019003161A/es unknown
- 2017-09-18 KR KR1020197011462A patent/KR102618843B1/ko active IP Right Grant
- 2017-09-18 AU AU2017329669A patent/AU2017329669A1/en active Pending
- 2017-09-18 EA EA201990711A patent/EA201990711A1/ru unknown
- 2017-09-18 TW TW106131993A patent/TWI817933B/zh active
- 2017-09-18 BR BR112019005516A patent/BR112019005516A2/pt unknown
- 2017-09-18 AR ARP170102576A patent/AR109539A1/es unknown
- 2017-09-18 EP EP17771725.3A patent/EP3515481A1/en active Pending
- 2017-09-18 WO PCT/EP2017/073473 patent/WO2018054837A1/en unknown
- 2017-09-18 NZ NZ751014A patent/NZ751014A/en unknown
- 2017-09-18 JP JP2019515517A patent/JP6952112B2/ja active Active
- 2017-09-18 CA CA3036291A patent/CA3036291A1/en active Pending
- 2017-09-18 US US15/706,889 patent/US10619169B2/en active Active
- 2017-09-18 UY UY0001037406A patent/UY37406A/es unknown
-
2019
- 2019-03-14 CL CL2019000655A patent/CL2019000655A1/es unknown
- 2019-03-15 PH PH12019500557A patent/PH12019500557A1/en unknown
- 2019-03-19 SA SA519401350A patent/SA519401350B1/ar unknown
-
2021
- 2021-07-07 JP JP2021112617A patent/JP2021176307A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TW201823458A (zh) | 2018-07-01 |
SA519401350B1 (ar) | 2022-06-22 |
US10619169B2 (en) | 2020-04-14 |
BR112019005516A2 (pt) | 2019-06-18 |
CN109715204A (zh) | 2019-05-03 |
UY37406A (es) | 2018-03-23 |
JP6952112B2 (ja) | 2021-10-20 |
KR20190053927A (ko) | 2019-05-20 |
NZ751014A (en) | 2023-03-31 |
CA3036291A1 (en) | 2018-03-29 |
CL2019000655A1 (es) | 2019-05-31 |
EA201990711A1 (ru) | 2019-09-30 |
CN109715204B (zh) | 2023-08-22 |
AU2017329669A1 (en) | 2019-03-21 |
MX2019003161A (es) | 2019-05-27 |
US20180080043A1 (en) | 2018-03-22 |
WO2018054837A1 (en) | 2018-03-29 |
JP2021176307A (ja) | 2021-11-11 |
JP2019533437A (ja) | 2019-11-21 |
TWI817933B (zh) | 2023-10-11 |
EP3515481A1 (en) | 2019-07-31 |
KR102618843B1 (ko) | 2024-01-02 |
PH12019500557A1 (en) | 2019-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR109539A1 (es) | Sitio de inserción orf70 de ehv | |
PH12018500965A1 (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
JP2020511115A5 (es) | ||
AR109451A1 (es) | Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión | |
RU2016136855A (ru) | Биомаркер-направленная многоцелевая иммунотерапия | |
AR113257A1 (es) | Virus chikungunya inmunogénico | |
CO2020007046A2 (es) | Plataformas de entrega crispr objetivo | |
EA201990717A1 (ru) | Новая вакцина против гриппа свиней | |
PH12019500578A1 (en) | New promoters | |
CO2020015707A2 (es) | Casetes de expresión de α-glucosidasa de ácido optimizado con codón y métodos de uso del mismo | |
WO2020047467A3 (en) | Cardiac cell reprogramming with myocardin and ascl1 | |
WO2022032196A3 (en) | Multiepitope vaccine cassettes | |
RU2016148309A (ru) | Хорошо переносимая и высокоспецифическая адаптированная рекомбиназа для рекомбинирования асимметричных участков-мишеней во множестве штаммов ретровирусов | |
AR101919A1 (es) | Elementos reguladores de zea mays y usos de estos | |
AR125194A2 (es) | Una planta transgénica que presenta un rendimiento mejorado y tolerancia al estrés abiótico, y método de obtención de dicha planta | |
BR112018072154A2 (pt) | construções genéticas recombinantes, métodos para produzir uma construção genética recombinante e para melhorar geneticamente uma planta, vetor, célula hospedeira e plantas | |
CO6420322A2 (es) | Anticuerpos anti-mst1r y usos de los mismos | |
AR105291A1 (es) | Métodos y conjuntos de elementos para la detección del oídio | |
WO2020043869A3 (en) | Methods and compositions for producing a virus | |
AR106436A1 (es) | Vector de ácido nucleico, método para producir una célula vegetal transgénica con el mismo, promotor empleado en el mismo, célula vegetal transgénica obtenida y polinucleótido aislado de dicho vector | |
AR108085A1 (es) | Moléculas de ácido nucleico fsh para el control de plagas de insectos | |
AR108748A1 (es) | Promotor vegetal y 3’ utr para la expresión de transgenes | |
AR100520A1 (es) | Métodos para mejorar la resistencia de las plantas a nemátodos de quiste de soja y composiciones de estos | |
WO2023044492A3 (en) | Neoantigen adjuvant and maintenance therapy | |
CO2023016037A2 (es) | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |